Impact of CYP polymorphisms, ethnicity and sex differences in metabolism on dosing strategies: The case of efavirenz

European Journal of Clinical Pharmacology

Volumn 70, Issue 4, 2014, Pages 379-389

  Naidoo, Panjasaram ^a   Chetty, Vasudevan V ^b   Chetty, Manoranjenni ^a,c  

^a UNIVERSITY OF KWAZULU NATAL   (South Africa)

^b Novartis ^*  (South Africa)

^c CERTARA UK LIMITED   (United Kingdom)

Author keywords

CYP2B6 polymorphisms; Dosing strategies; Efavirenz; Ethnicity; Metabolism; Plasma concentration variations; Sex

Indexed keywords

CYTOCHROME P450 2B6; DRUG METABOLIZING ENZYME; EFAVIRENZ; XENOBIOTIC AGENT; BENZOXAZINE DERIVATIVE; CYTOCHROME P450; RNA DIRECTED DNA POLYMERASE INHIBITOR;

BLOOD LEVEL; CLINICAL TRIAL (TOPIC); DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG INFORMATION; DRUG METABOLISM; ETHNICITY; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PREVALENCE; PRIORITY JOURNAL; REVIEW; SEX; SEX DIFFERENCE; DRUG INACTIVATION; GENETICS; METABOLISM; SEXUAL DEVELOPMENT;

BENZOXAZINES; CYTOCHROME P-450 ENZYME SYSTEM; GENOTYPE; HUMANS; INACTIVATION, METABOLIC; POLYMORPHISM, GENETIC; REVERSE TRANSCRIPTASE INHIBITORS; SEX CHARACTERISTICS;

EID: 84896491775     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-013-1634-1     Document Type: Review

References (92)

1. Zanger UM, Klein M (2013) Pharmacogenetics of cytochrome P450 2B6 (CYP2B6): advances on polymorphisms, mechanisms, and clinical relevance. Front Genet 4: 24 Published online 2013 March 5.doi:10.3389/fgene.2013.00024 DOI:10.3389%2Ffgene.2013.00024#pmc-ext
2. Bradford LD (2002) CYP2D6 allele frequency in European Caucasians, Asians, Africans and their descendants. Pharmacogenomics 3:229-243
3. Zhou SF, Liu JP, Chowbay B (2009) Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metab Rev 41:89-295
4. Li J, Bluth MH (2011) Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy. Pharmacogenomics Personalized Med 4:11-33
5. Alessandrini M, Asfaha S, DodgenTM, Warnich L, Pepper M (2013) Cytochrome P450 pharmacogenetics in African populations. Drug Metab Rev 45:253-275
6. Frueh FW, Amur S, Mummaneni P et al (2008) Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 28:992-998
7. Soldin OP, Mattison DR (2009) Sex differences in pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 48(3):143-157
8. Chetty M, Mattison DR, Rostami-Hodjegan A (2012) Sex differences in the clearance of CYP3A4 substrates: exploring possible reasons for the substrate dependency and lack of consensus. Curr Drug Metab 13:778-786
9. Young SD, Britcher SF, Tran LO et al (1995) L-743,726(DMP-266): a novel, highly potent non-nucleoside inhibitor of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 39(12):2602-2605
10. th Conference on Retroviruses and Opportunistic Infections Chicago ((Abstract) 698)
11. Riddler S, Kahn J, Hicks C et al. (1998) Durable clinical anti-HIV-1 activity (72 weeks) and tolerability for Efavirenz (DMP 266) in combination with Indinavir (IDV) [DMP266-003, Cohort IV]. 12th World AIDS Conference Geneva June 28-July 3 1998 (abstract 12359).
12. Vrouenraets SME, Wit FWNW, Van Tongeren J, Lange JMA (2007) Efavirenz: a review. Expert Opin Pharmacother 8(6): 851-871 (Pubitemid 46736458)
13. Marzolini C, Telenti A, Decosterd LA, Greub G, Biollaz J, Buclin T (2001) Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients. AIDS 15:71-75 (Pubitemid 32055781)
14. Núñez M, González de Requena D, Gallego L, Jiménez-Nácher I, González-Lahoz J, Soriano V (2001) Higher efavirenz plasma levels correlate with development of insomnia. J Acquir Immune Defic Syndr 28:399-400
15. Csajka C et al (2003) Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharmacol Ther 73:20-30 (Pubitemid 36158483)
16. Gutiérrez F et al (2005) Prediction of neuropsychiatric adverse events associated with long-term efavirenz therapy, using plasma drug level monitoring. Clin Infect Dis 41:1648-1653 (Pubitemid 41691605)
17. van Luin M et al (2009) Efavirenz dose reduction is safe in patients with high plasma concentrations and may prevent efavirenz discontinuations. J Acquir Immune Defic Syndr 52:240-245
18. Gazzard BG (1999) Efavirenz in the management of HIV infection. Int J Clin Pract 53:60-64
19. Arab-Alameddine M et al (2009) Pharmacogenetics-based population pharmacokinetic analysis of efavirenz in HIV-1-infected individuals. Clin Pharmacol Ther 85:485-494
20. Sánchez A, Cabrera S, Santos D, Paz Valverde M, Fuertes A, Domínguez-Gil A et al (2011) Population pharmacokinetic/ pharmacogenetic model for optimization of Efavirenz therapy in Caucasian HIV-infected patients. Antimicrob Agents Chemother 55(11):5314
21. Bacheler LT, Anton ED, Kudish P et al (2000) Human immunodeficiency virus type 1 mutations selected in patients failing efavirenz combination therapy. Antimicrob Agents Chemother 44(9):2475-2484 (Pubitemid 30650898)
22. Deeks SG (2001) International perspectives on antiretroviral resistance. Nonnucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 26(suppl 1):S25-S33
23. Smith PF, DiCenzo R, Morse GD (2001) Clinical pharmacokinetics of Non-nucleoside reverse transcriptase inhibitors. Clin Pharmacokinet 40(12):893-905 (Pubitemid 34066687)
24. Tashima KT, Caliendo AM, Ahmad M et al (1999) Cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) suppression and efavirenz drug concentrations in HIV-1-infected patients receiving combination therapy. J Infect Dis 180:862-4 (Pubitemid 29411379)
25. Reddy YS, Gotzkowsky SK, Eron JJ et al (2002) Pharmacokinetic and pharmacodynamic investigation of efavirenz in the semen and blood of human immunodeficiency virus type 1-infected men. J Infect Dis 186(9):1339-1343 (Pubitemid 35193014)
26. Ghosn J, Chaix ML, Peytavin G et al (2004) Penetration of enfuvirtide, tenofovir, efavirenz and protease inhibitors in the genital tract of HIV-1-infected men. AIDS 18(14):1958-1961 (Pubitemid 39313214)
27. Villani P, Regazzi MB, Castelli F, Viale P, Torti C, Seminari E, Maserati R Pharmacokinetics of efavirenz (EFV) alone and in combination therapy with nelfinavir (NFV) in HIV-1 infected patients. Br J Clin Pharmacol 48:712-715
28. Ward BA et al (2003) The cytochrome P450 2B6 (CYP2B6) is the main catalyst of efavirenz primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity. J Pharmacol Exp Ther 306:287-300 (Pubitemid 36734384)
29. Cho DY, Ogburn ET, Jones D, Desta Z (2011) Contribution of N-glucuronidation to Efavirenz elimination in vivo in the basal and rifampin-induced metabolism of Efavirenz. Antimicrob Agents Ch 55:1504-1509
30. Desta Z, Saussele T,Ward B et al (2007) Impact of CYP2B6 polymorphism on hepatic efavirenz metabolism in vitro. Pharmacogenomics 8: 547-558 (Pubitemid 46947859)
31. Mouly S, Lown KS, Kornhauser D et al (2002) Hepatic but not intestinal CYP3A4 displays dose-dependent induction by efavirenz in humans. Clin Pharmacol Ther 72:1-9 (Pubitemid 34833182)
32. Mutlib AE et al (1999) Identification and characterization of efavirenz metabolites by liquid chromatography/mass spectrometry and high field NMR: species differences in the metabolism of efavirenz. Drug Metab Dispos 27:1319-133
33. Faucette SR, Zhang TC, Moore R, Sueyoshi T et al (2007) Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J Pharm Exp Ther 320:72-80 (Pubitemid 46025721)
34. Ngaimisi E, Mugusi S, Minzi OM et al (2010) Long-term Efavirenz auto-induction and its effect on plasma exposure in HIV patients. Clin Pharmacol Ther 86:676-684
35. Lang T, Klein K, Fischer J et al (2001) Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415 (Pubitemid 32656581)
36. Haas D, Gebretsadik T, Mayo G et al (2009) Associations between CYP2B6 polymorphisms and pharmacokinetics after a single dose of nevirapine or Efavirenz in African Americans. J Infect Dis 199:872-80
37. Zanger UM, Klein K, Saussele T et al (2007) Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance. Pharmacogenomics 8:743-759 (Pubitemid 47288975)
38. Robertson SM, Maldarelli F, Natarajan V et al (2008) Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects. J Acquir Immune Defic Syndr 49:513-519
39. Joshi AS, Barrett JS, Fiske WD et al. (1999) Population pharmacokinetics of efavirenz in phase II studies and relationship with efficacy. 39 th Interscience Conference on Antimicrobial Agents and Chemotherapy San Francisco [Poster 1201]
40. Gallego LA, Barreiro P, del Río R, de Requena DG et al (2004) Analyzing sleep abnormalities in HIV-infected patients treated with Efavirenz. Clin Infect Dis 38:430-432 (Pubitemid 38200124)
41. Van Leth F, Kappelhoff BS, Losso JMS, Boron-Kaczmarska A et al (2006) The effect of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirapine or efavirenz-based first-line HAART. AIDS Res Hum Retrov 22(3):232-239
42. Ståhle L, Moberg L, Svensson JO, Sönnerborg A (2004) Efavirenz plasma concentrations in HIV-infected patients: inter- and intraindividual variability and clinical effects. Ther Drug Monit 26(3):267-270
43. Kappelhoff B, van Leth F, Robinson PA, MacGregor TR, Baraldi E, Montella F, Uip DE, Thompson MA, Russell DB, Lange JMA, Beijnen JH, Huitema (2005) ADR for the 2NN study group. Are adverse events of nevirapine and Efavirenz related to plasma concentrations? Antivir Ther 10:489-498 (Pubitemid 41059195)
44. Josephson F, Andersson MCH, Flamholc L et al (2010) The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients. Eur J Clin Pharmacol 66:349-357
45. La Porte CJ, Back DJ, Blaschke T et al (2006) Updated guideline to perform therapeutic drug monitoring for antiretroviral agents. Rev Antivir Ther 3:4-14
46. Burger D, van der Heiden I, La Porte C et al (2005) Inter-patient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism. Br J Clin Pharmacol 61:2148-154
47. Rodríguez-Nóvoa S, Barreiro P, Jimenez-Nacher I, Soriano V (2006) Overview of the pharmacogenetics of HIV therapy. Pharmacogenomics J 6:234-245 (Pubitemid 44137950)
48. Swart M, Skelton M, Ren Y, Smith P, Takuvac S, Dandara C (2013) High predictive value of CYP2B6 SNPs for steady-state plasma efavirenz levels in South African HIV/AIDS patients. Pharmacogenet Genomics 23:415-427
49. Nakajima M, Fukami T, Yamanaka H et al (2006) Comprehensive evaluation of variability in nicotine metabolism and CYP2A6 polymorphic alleles in four ethnic populations. Clin Pharmacol Ther 80: 282-97 (Pubitemid 44313906)
50. Fukami T, Nakajima M, Yoshida R et al (2004) A novel polymorphism of human CYP2A6 gene CYP2A6*17 has an amino acid substitution (V365M) that decreases enzymatic activity in vitro and in vivo. Clin Pharmacol Ther 76:519-27 (Pubitemid 39601542)
51. Kwara A, Lartey M, Sagoe KW, Rzek N, CourtMH (2009) CYP2B6 (c.516G>T) and CYP2A6 (*9B and/or *17) polymorphisms are independent predictors of efavirenz plasma concentrations in HIVinfected patients. Br J Clin Pharmacol 67(4):427-436
52. Li J, Menard V, Benish RL et al (2012) Worldwide variation in human drug-metabolism enzyme genes CYP2B6 and UGT2B7: implications for HIV/AIDS treatment. Pharmacogenomics 13(5): 555-570
53. Haas DW, Ribaudo J, Kim RB et al (2004) AIDS 18:2391-2400
54. Rodríguez-Novoa S, Barreiro P, Rendon A, Jimenez-Nacher I, Gonzalez, Lahoz J, Soriano V (2005) Influence of 516G4T polymorphisms at the gene encoding the CYP450-2B6 isoenzyme on efavirenz plasma concentrations in HIV-infected subjects. Clin Infect Dis 40:1358-1361 (Pubitemid 40570249)
55. Ribaudo HJ, Haas DW, Tierney C et al (2006) Pharmacogenetics of plasma Efavirenz exposure after treatment discontinuation: an adult AIDS clinical trials group study. Clin Infect Dis 42:401-7 (Pubitemid 43122320)
56. Maimbo M, Kiyotani K, Mushiroda T, Masimirembwa C, Nakamura Y (2012) CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans. Eur J Clin Pharmacol 68:267-271
57. Gatanaga H, Hayashida T, Tsuchiya K et al (2007) Successful efavirenz dose reduction in HIV type 1-infected individuals with cytochrome P450 2B6 *6 and *26. Clin Infect Dis 45:1230-1237 (Pubitemid 47580326)
58. Wyen C, Hendra H, VogelMet al (2008) Impact of CYP2B6 983 T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients. J Antimicrob Chem 61:914-918 (Pubitemid 351436194)
59. Rotger M, Tegude H, Colombo S et al (2007) Predictive value of known and novel alleles of CYP2B6 for efavirenz plasma concentrations in HIVinfected individuals. Clin Pharmacol Ther 81:557-66 (Pubitemid 46454205)
60. Siccardi M, Almond L, Schipani A, Csajka C, Marzolini C et al (2012) Pharmacokinetic and pharmacodynamic analysis of Efavirenz dose reduction using an in vitro-in vivo extrapolation model. Clin Pharmacol Ther 92(4):494-502
61. Rakhmanina NY, van den Ankerb JN (2010) Efavirenz in the therapy of HIV infection. Expert Opin Drug Metab Toxicol 6(1):95-103
62. Klein K, Lang T, Saussele T et al (2005) Genetic variability of CYP2B6 in populations of African and Asian origin: allele frequencies, novel functional variants, and possible implications for anti-HIV therapy with Efavirenz. Pharmacogenet Genomics 15:861-873 (Pubitemid 41666768)
63. Tsuchiya K, Gatanaga H, Tachikawa N et al (2004) Homozygous CYP2B6 *6 (Q172H and K262R) correlates with high plasma efavirenz concentrations in HIV-1 patients treated with standard efavirenz-containing regimens. Biochem Biophy Res Commun 319:1322-1326 (Pubitemid 38759555)
64. Yasuda SU, Zhang L, Huang SM (2008) The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharm Ther 84:417-423
65. Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr (2002) Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 40:507-519 (Pubitemid 35331935)
66. Hitti J, Rosenkranz S, Cohn S et al. for the Adult AIDS Clinical Trial Group Study 398. (2004) Sex and weight as covariates in the pharmacokinetics of efavirenz, indinavir, and nelfinavir. In: Program and abstracts of the 11th Conference on Retroviruses and Opportunistic Infections; February 8-11, 2004; San Francisco, Calif. Abstract 604
67. Habtewold A, AmogneW,Makonnen E et al (2011) Long-term effect of efavirenz auto-induction on plasma/peripheral blood mononuclear cell drug exposure and CD4 count is influenced by UGT2B7 and CYP2B6 genotypes among HIV patients. J Antimicrob Chemother 66:2350-2361
68. Zhu M, Kaul S, Nandy P, Grasela DM, Pfister M (2009) Model-based approach to characterize efavirenz auto-induction and concurrent enzyme induction with carbamazepine. Antimicrob Agents Chemother 53:2346-2353
69. Müller F, Fromm MF (2011) Transporter-mediated drug-drug interactions. Pharmacogenomics 12(7):1017-37
70. de Maat MMR, Ekhart GC, Huitema DR, Koks CHW, Mulder JW, Beijen JH (2003) Drug interactions between antiretroviral drugs and Co-medicated agents. Clin Pharmacokinet 42(3):223-282
71. Talakad JC, Kumar S, Halpert JR (2009) Decreased susceptibility of the cytochrome P450 2B6 variant K262R to inhibition by several clinically important drugs. Drug Metab Dispos 37(3):644-650
72. Robertson SM, Penzak SR, Lane J, Pau AK, Mican JM (2005) A potentially significant interaction between Efavirenz and phenytoin: a case report and review of the literature. Clin Infect Dis 41(2):e15- e18. doi:10.1086/431208
73. Byakika-Kib wika P, Lamorde M, Mayito J et al (2012) Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults. J Antimicrob Chemother 67(9):2213-21
74. Drugs.Com. Drugs Information Online, Efavirenz Drug Interactions (2013) http://www.drugs.com/drug-interactions/efavirenz-index.html Accessed 29.7.13
75. University of California, San Francisco, HIV InSite, Centre for HIV Information, (2013) http://hivinsite.ucsf.edu/insite?page=ar-00-02¶m= 9&post=4 Accessed 26.7.2013
76. ARV Interactions, National HIV, HCW Hotline, (2012) http://www.mic.uct. ac.za/wp-content/uploads/2012/07/ARV-Interactions-20124.pdf Accessed 29.7.13
77. UCT (University of Cape Town), Clinical Pharmacology Division, FHS. South African Medicines Formulary, Health and Medical Publishing Group of the South African Medical Association. Ed.; Rossiter D: Rondebosch, CT, South Africa, (2012) pg 339
78. Sustiva 600 mg (2013) Summary of products characteristics updated 25.6.2013http://www.medicines.org.uk/emc/medicine/11284 Accessed 30.7.13
79. ACTG drug Interaction Database, Clarithromycin versus Efavirenz http://tprc.pharm.buffalo.edu/home/di-search/ Accessed 29.7.13
80. Medline Plus, Natural Medicines Comprehensive Database, Garlic update (2011) http://www.nlm.nih.gov/medlineplus/druginfo/natural/300.html Accessed 1.8.2013
81. Marc W, Benator D, Peloquin CA et al (2008) Tuberculosis trials consortium. Evaluation of the drug interaction between rifabutin and Efavirenz in patients with HIV infection and tuberculosis. Clin Infect Dis 41(9):1343-1349 (Pubitemid 41532682)
82. Ren Y, Nuttall JJ, Eley BS et al (2009) Effect of rifampicin on efavirenz pharmacokinetics in HIV-infected children with tuberculosis. J Acquir Immune Defic Syndr 50(5):439-43. doi:10.1097/QAI.0b013e31819c33a3
83. Yenny, Nafrialdi, Djoerban Z, Setiabudy R (2011) Pharmacokinetic interaction between efavirenz and rifampicin in healthy volunteers. Int J Clin Pharmacol Ther 49(2):162-8
84. Kwara A, Tashima KT, Dumond JB et al (2011) Modest but variable effect of rifampin on steady-state plasma pharmacokinetics of Efavirenz in healthy African-American and Caucasian volunteers. Antimicrob Agents Chemother 55(7):3527-3533
85. Hasse B, Gunthard HF, Bleiber G, Krause M (2005) Efavirenz intoxication due to slow hepatic metabolism. Clin Infect Dis 40:e22-e23
86. Jonsson EN, Karlsson MO (1999) Xposec-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEN. Comput Methods Programs Biomed 58:51-64 (Pubitemid 29049052)
87. Matteelli A, Regazzi M, Villani P et al (2007) Multiple-dose pharmacokinetics of efavirenz with and without the use of rifampicin in HIV-positive patients. Curr HIV Res May 5(3):349-53
88. López-Cortés LF, Ruiz-Valderas R, Viciana P et al (2002) Pharmacokinetic interactions between efavirenz and rifampicin in HIV-infected patients with tuberculosis. Clin Pharmacokinet 41(9): 681-90
89. Cabrera SE, Santos D, Valverde MP et al (2009) Influence of the cytochrome P450 2B6 genotype on population pharmacokinetics of Efavirenz in human immunodeficiency virus patients. Antimicrob Agents Chemo 53:2791-2798
90. Rekic D, Roshammar D, Mukonzo J, Ashton M (2011) In silico prediction of efavirenz and rifampicin drug-drug interaction considering weight and CYP2B6 phenotype. Br J Clin Pharmacol 71:536-543
91. Xu C, Quinney SK, Guo Y, Hall SD, Li L, Desta Z (2013) CYP2B6 Pharmacogenetics-Based in vitro-in vivo Extrapolation (IVIVE) of Efavirenz Clearance by PBPK Modelling DMD Fast Forward. Published as doi:10.1124/dmd.113. 051755
92. Turpeinen M, Zanger UM (2012) Cytochrome P450 2B6: function, genetics, and clinical relevance. Drug Metab Drug Interact 27(4): 185-197